Objective: to comparatively assess the weighted average costs associated with the use of alogliptin-pioglitazone combination versus glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Material and methods. A retrospective study involved pharmacoeconomic analysis. including cost-minimization analysis and budget impact analysis. https://www.roneverhart.com/Grace-Design-M801-MK2-High-Fidelity-p15168/